Tag:

Alere

Latest Headlines

Latest Headlines

Alere rethinks BBI IPO

So much for those IPO plans. Alere last week decided against taking its BBI Diagnostics businesses public on the London Stock Exchange, citing equity market conditions in the U.K.

Alere gets FDA clearance for rapid influenza test

Alere's i Influenza A & B test, which the company says is the first and only molecular test to detect and differentiate beween the two types, received FDA clearance on June 16.

It's official: Alere is spinning off its diagnostics biz

BBI Diagnostics Group provided details off its plans to be traded on the London Stock Exchange in June 2014 in a May 19 statement. The IPO will consist of the sale of the 25% indirect ownership interest in BBI held by parent company Alere. 

Alere recalls test strips after patient deaths

In reaction to three patient deaths associated with its INRatio2 PT/INR Professional Test Strips, Alere initiated a voluntary Class I recall of the products.

Alere shakes up boardroom, embarks on strategic review

Still finding its footing after irked investors mounted a proxy challenge last year, Alere is shuffling its top ranks and setting out on a review of its operations, a move that could spell more divestitures.

Alere plans to spin off a subsidiary in a U.K. IPO

In the wake of bitter proxy fight, diagnostics leader Alere revealed plans to trim off some its noncore businesses, planning an IPO in an effort to keep its promise to investors worried about the company's mounting debts.

Alere improves Q4 numbers through revenue growth and cost cuts

Alere's 2013 fourth quarter reflected a healthy boost in revenue and a drastic reduction in net losses over a year ago. The gains came, in part, from organic growth and cutting costs in areas including research and development and administration.

Alere's new HIV test could gain momentum from Affordable Care Act

If timing is everything, then Alere stands to gain plenty, thanks to the Affordable Care Act. The new law mandates reimbursement for HIV testing from both public and private insurers, and Alere recently rolled out a new, first-of-its-kind combo HIV diagnostic in the U.S.

Alere wins FDA nod for HIV test, struggles on the Street

Alere is trying to get back to business as usual now that it has shaken off a proxy challenge, winning the FDA's blessing for a combo HIV diagnostic as it works to convince investors it has a plan for the future.

Alere declares victory in proxy challenge

After months of backbiting and accusations, Alere has come out the other end of a proxy fight, getting all four of its board nominees elected and fending off an activist investor that wanted the company to pare down.